key: cord-0261665-771jjglk authors: Lubetzky, M.; Sukhu, A.; Zhao, Z.; Rand, S.; Sharma, V.; Sultan, S.; Kapur, Z.; Albakry, S.; Hauser, N.; Marku-Podvorica, J.; Craig-Schapiro, R.; Lee, J. R.; Salinas, T.; Aull, M.; Kapur, S.; Cushing, M.; Dadhania, D. M. title: SARS-CoV-2 Antibody Response in Patients Undergoing Kidney Transplantation date: 2021-07-28 journal: nan DOI: 10.1101/2021.07.25.21261066 sha: eb42eb95bc7e5845dc8b87401695691f1b768161 doc_id: 261665 cord_uid: 771jjglk Abstract The response of the immune system to COVID-19 in end stage kidney disease patients who undergo kidney transplantation has yet to be described. We report data on 72 patients who underwent SARS-CoV-2 antibody testing both before and after kidney transplantation and were followed for a median of 186 days (range 83, 277). Of the 25 patients with a positive antibody test at the time of transplant, 17 (68%) remained positive after transplantation. Patients were significantly more likely to have a persistently positive test if they reported a symptomatic COVID-19 infection prior to transplant (p=0.01). SARS-CoV-2 IgG index values were measured in a subset of kidney transplant recipients and compared to wait -listed dialysis patients. These assays demonstrated a more significant decline in IgG (58% versus 14% p = 0.008) in transplant recipients when compared to dialysis patients tested during the same time period. Additional analysis of the quality of the immune response measuring the binding of SARS-CoV-2 antibodies to the receptor-binding domain (RBD binding), the antibody neutralizing capability, and the antibody avidity demonstrated a more pronounced effect when comparing pre-transplant values to post-induction therapy/post transplant values. The attenuated IgG response seen in transplant patients compared to dialysis patients after induction therapy requires further study. These data have important implications for post-transplant management of vaccinated dialysis patients. Currently, over 33 million cases of COVID-19 have been reported in the United States. Recent population-based studies have looked specifically at the prevalence of antibodies to SARS-CoV-2 in New York and estimate that anywhere from 6% to 22% of New Yorkers have SARS-CoV-2 antibodies [1] [2] [3] . Estimates in the dialysis population have been even higher and range from 6.9%, to 69% 4, 5 . With past infection rates this high, patients are presenting for kidney transplants with a prior history of COVID- 19 illness, yet data are lacking on the durability of the immune response after induction immunosuppression. To better understand the changes that occur with immunosuppressive therapies, we followed SARS-CoV-2 antibody presence in transplant recipients before and after kidney transplant, specifically after the initiation of lymphocyte depleting induction immunotherapy and maintenance immunosuppression. We also compared SARS-CoV-2 antibody response in our cohort of transplant patients to a cohort of wait-listed dialysis patients over a similar time period to determine the effects of immunosuppression on antibody response. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint description of the study cohort is shown in Figure 1 . Demographic data were collected on patients who met inclusion criteria (Table 1) . All patients in the study were initially screened for SARS-CoV-2 antibodies upon admission for kidney transplant in the clinical setting using a clinically validated test targeting the RBD of the S1 spike protein (S-RBD) to detect SARS-CoV-2 antibodies which gives either a positive or negative result. To do further quantitative analysis on a subset of patients, all patients with a positive test were reviewed for availability of left over sera in our tissue-typing laboratory. The Weill Cornell histocompatibility lab performing donor specific antibody testing stores left over sera for transplant candidates and transplant recipients for 6 months. Any patient with a positive pre-transplant SARS-CoV-2 antibody, who had at least 1 pre-transplant and 1 post-transplant stored sample available was included in the quantitative analysis (n=10). In addition, sequential sera samples from 4 wait-listed dialysis patients with SARS-CoV-2 antibodies was also available for testing. A detailed description of these patients is presented in Table 2 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Testing for the quantitative 10 transplant recipients and 4 dialysis patients testing was performed using the following assays: 1) measurement of IgG Index value and IgM Index value using the SARS-CoV-2 Pylon 3D analyzer (ET Healthcare) as previously described 6 , 2) SARS-CoV-2 total receptor binding domain (RBD) assay to measure the overall binding between SARS-CoV-2 antibodies and the RBD of the virus S protein, 3) SARS-CoV-2 Antibody Avidity Assay that measures the rate of SARS-CoV-2 specific antibody dissociation from RBD, which is inversely correlated with the antibody avidity, and 4) SARS-CoV-2 Surrogate Neutralizing Antibody Assay (SNAb) which is a competitive binding assay that measures the percentage of RBD-ACE2 binding and inversely correlates with the SNAb binding inhibition (neutralizing activity). GraphPad Prism 9 was used to determine median, mean and standard deviation for all data. Mann-Whitney t-test was used to calculate p values for continuous variables, Wilcoxon t-test was used to calculate p values for paired samples and Fisher's exact test was used to calculate p values for categorical variables. Patient demographics and immunosuppression regimens for all patients, subdivided according to pre-transplant antibody status, is shown in Table 1 . Patients in both groups were similar. Follow up creatinine at 1-month, 3-months and 6 months was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. Twenty-six samples from 10 patients with history of COVID-19 illness who were transplanted during the study period had semi-quantitative analysis to measure their IgG and IgM levels before and after transplant. SARS-CoV-2 IgG levels were evaluated at 4 time points: 1) pre-transplant, 2) 1-60 days after transplant, 3) 61-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint 120 days after transplant, and 4) more than 120 days after transplant. The percent reduction of IgG from pre-transplant levels at each of the time points was 44%, 72% and 91% respectively and is demonstrated in To determine if the changes seen in SARS-CoV-2 antibodies over time was similar to that of non-transplant patients, 20 samples from the transplant cohort and stored sera from a cohort of wait-listed dialysis patients with a positive SARS-CoV-2 antibody from the same time frame were tested. Characteristics of patients from both cohorts are listed in Table 2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. while a significant increase in avidity over time was found. The percent reduction of IgG in transplant patients (53%) was significantly greater than the reduction for dialysis patients (14%) (p=0.008). The percent reduction in the total receptor binding domain assay for transplant patients (75% reduction) was significantly greater than the reduction for dialysis patients (1.5%) ( p=0.002). There was no significant difference between the percent changes seen in transplant and dialysis patients for the avidity of the antibody (19.5% increase in transplant versus 6% increase in dialysis, P=0.08) or the neutralizing capabilities of the antibody (119% decrease in transplant versus 16.5% decrease for dialysis patients, P=0.43). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; In this study we evaluated SARS-CoV-2 antibody levels before and after the initiation of induction and maintenance immunosuppression in kidney transplant recipients. This is the first report to date to describe the antibody response in patients who recently received induction immunosuppression for kidney transplant. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. 11 . Their work demonstrates the need to better understand patient characteristics that predict long-lasting immunity post vaccination and to follow patients closely even after receiving 2 doses of an approved vaccine. Immunosuppressed patients may not mount an effective immune response to the vaccine and this may be dependent on variety of factors. These factors require careful prospective studies that are ongoing. The optimal timing for vaccination, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint measuring antibody titers after transplantation, and risks and benefits of a third dose remain to be determined. Our quantitative analysis of transplant and wait-listed dialysis patients demonstrates that in both cohorts IgG levels decrease over time. To our knowledge this is first report to compare antibody response in dialysis and transplant patients. Our results are also consistent with previous studies in non-transplant populations that demonstrate a decline in IgG antibody levels over time [12] [13] [14] [15] 14, [16] [17] [18] [19] [20] in that both show increased avidity of SARS-CoV-2 antibody over time, which reflects both affinity maturation and multivalent binding development after infection. We also observed increased antibody avidity over time, which is consistent with the notion All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint of continued evolution of the humoral immune response and supported by previous evidence that memory B cell response continues to evolve and express antibodies with increased neutralizing potency and breadth 14, 15 . The extent to which immunosuppression plays a role in these particular responses is more difficult to assess given the small sample size, however, it does appear the response in transplant patients overall is attenuated when compared to the dialysis controls. Larger studies are needed in both transplant and dialysis patients to better evaluate these findings. Our data set has several limitations. First, there were only a small number of samples that were available for sequential testing and there was only a short duration of follow-up. In the cohort of patients who underwent quantitative and qualitative testing, all received lymphocyte depleting induction therapy and therefore it is unknown whether results would be similar if patients had another type of induction therapy, nor could we compare whether the attenuated response would also be seen in patients who underwent induction with IL-2 receptor blocking agents. Such data is important as some have suggested using less potent immunosuppression, especially for induction therapy in the COVID era. Finally, dialysis patients are known to have an impaired immune response 21 and therefore the study would be strengthened by having a non dialysis cohort to compare our findings as well. It is reassuring, however, that overall our findings mirror that done by other centers in both transplant and non-transplant patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; Overall, this is the first study to describe the changes in humoral immunity in kidney transplant recipients pre and post-transplantation. We have demonstrated that (1) there is significant heterogeneity in the durability of the humoral response to SARS-CoV-2 in the transplant population and (2) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 28, 2021. ; https://doi.org/10.1101/2021.07.25.21261066 doi: medRxiv preprint Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence Antibodies and Outcomes Among Outpatient Maintenance Hemodialysis Patients Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays COVID-19 infection in kidney transplant recipients at the epicenter of pandemics Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot Study Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection Prevalence and Predictors of SARS-CoV-2 Antibodies among Solid Organ Transplant Recipients with Confirmed Infection Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Evolution of antibody immunity to SARS-CoV-2 TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients Kinetics of viral load and antibody response in relation to COVID-19 severity Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection Aspects of immune dysfunction in end-stage renal disease We would like to thank the entire Division of Nephrology and Transplantation for their intellectual contributions to the manuscript, and specifically Dr. Manikkam Suthanthiran for his guidance and mentorship. In addition we would like to thank All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 28, 2021.